In melanoma, intratumour heterogeneity of BRAF mutations is described in more than 10% of cases11, 13, 14, 58 so, depending on the zone biopsied within a tumour, the determination of BRAF mutations may be wild‐type or mutant, with clear clinical implications (see Figure 1). This evidence concerns the gene BRAF and neoplasm.